stockrowPasithea Therapeutics Corp.
KTTA Healthcare Biotechnology
- EPS
- +75.8%
- Free cash flow
- −21.7%
Quarter to June 2026, against a year earlier
Follow KTTA
Alert me
Pasithea Therapeutics Corp. (KTTA) EV/Sales
As of 6 November 2026, Pasithea Therapeutics Corp. (KTTA) trades at a EV/Sales of −55.8×. Over the past ten years it has ranged from −106× (December 2022) to 13.8× (November 2025); the current reading is higher than 19% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2022 | −34.6× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2022 | −32.7× | — |
| Sep 2022 | −30.5× | — |
| Jun 2022 | 0.0× | — |
| Mar 2022 | 0.0× | — |
| 1 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| KTTA Pasithea Therapeutics Corp. | −55.8× |
| ACTU Actuate Therapeutics, Inc. compare | n/m |
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR compare | n/m |
| JSPR Jasper Therapeutics, Inc. compare | n/m |
| ESLA Estrella Immunopharma, Inc. compare | n/m |
| NCEL NewcelX Ltd. compare | n/m |
| CNTX Context Therapeutics Inc. compare | n/m |
| COCP Cocrystal Pharma, Inc. compare | 9.0× |
| QNTM Quantum Biopharma Ltd. compare | 18.5× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)